Michigan Medicine begins recruitment for phase 3 of Janssen COVID-19 vaccine trial

Posted at 9:33 AM, Oct 12, 2020
and last updated 2020-10-12 09:33:11-04

The University of Michigan announced Monday that Michigan Medicine has begun recruiting for phase 3 of the Janssen COVID-19 clinical trial.

The trial, known as the ENSEMBLE study, will evaluate a vaccine for the prevention of COVID-19 as part of a double-blind phase 3 clinical trial.

U-M is one of several sites across the world supporting the trial, which hopes to enroll up to 60,000 people worldwide.

“Michigan Medicine is committed to supporting the continued study of the investigational Janssen vaccine and other vaccine candidates. These trials are crucial to moving us toward an effective vaccine,” says Marschall Runge, M.D., Ph.D., Dean, U-M Medical School, Executive Vice President, Medical Affairs and CEO, Michigan Medicine.

This is the second trial being done on COVID-19 vaccines at U-M. They are also doing an AstraZeneca trial.

Enrollment is open for both trials now, and you can apply to be part of it by visiting